AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Pliant Therapeutics, Inc.
Video analysis: PLRX
All videosNo video analysis for this stock yet. Request one from our team.
News: PLRX
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations. Profitability This table compares Pliant Therapeutics
Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRX
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Pliant Therapeutics, Inc. (NASDAQ: PLRX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 536,081 shares of the company's stock, valued at approximately $611,000. Connor Clark and Lunn Investment Management
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise
